Related Experiment Video
Updated: Apr 12, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Kidney cancer: current and novel treatment options
1Presented by Eric Jonasch, MD, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, and Director of the Von Hippel-Lindau Clinical Center at The University of Texas MD Anderson Cancer Center and co-Director of the MD Anderson Kidney Cancer Research Program, Houston, Texas.
Abstract:
Antiangiogenic therapies remain the standard of care in the front-line setting for renal cell carcinoma, although vascular endothelial growth factor (VEGF) blockade is not sufficient, and many patients do not respond to such treatment. With a host of approved agents, questions arise as to how best to use them in both initial and secondary treatments. Optimal sequences are currently being tested in various clinical trials. Because approximately 20% of patients exhibiting primary resistance to these anti-VEGF therapies, new therapies are needed. Novel therapies such as MET and AXL inhibitors as well as checkpoint antibodies hold promise for the future.
Insights
Antiangiogenic therapies are standard for renal cell carcinoma but often insufficient. New treatments targeting MET, AXL, and checkpoint inhibitors are needed for patients resistant to vascular endothelial growth factor (VEGF) blockade.
Area of Science:
- Oncology
- Medical Research
Background:
- Antiangiogenic therapies targeting vascular endothelial growth factor (VEGF) are the standard first-line treatment for renal cell carcinoma (RCC).
- VEGF blockade is not universally effective, with a significant portion of patients exhibiting primary resistance or developing resistance over time.
- The optimal sequencing of available anti-VEGF agents for initial and subsequent treatments is an ongoing area of clinical investigation.
Purpose of the Study:
- To review the current landscape of antiangiogenic therapies in renal cell carcinoma.
- To highlight the unmet need for novel therapeutic strategies due to primary and acquired resistance.
- To discuss promising new therapeutic targets and agents for renal cell carcinoma treatment.
Main Methods:
- Review of current clinical practices and approved antiangiogenic agents for renal cell carcinoma.
- Analysis of clinical trial data regarding treatment sequencing and patient response.
- Exploration of emerging therapeutic targets and investigational agents.
Main Results:
- A significant percentage of patients (approximately 20%) show primary resistance to anti-VEGF therapies.
- Questions remain regarding the optimal use and sequencing of current antiangiogenic agents.
- Emerging therapies targeting MET, AXL, and immune checkpoints show potential.
Conclusions:
- Despite advances, antiangiogenic therapies have limitations in renal cell carcinoma treatment.
- There is a critical need for novel therapeutic approaches to overcome resistance to VEGF blockade.
- MET inhibitors, AXL inhibitors, and checkpoint antibodies represent promising future directions for renal cell carcinoma management.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:21Cancer Survival Analysis